Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

Next Previous
Trial Profile

A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BOLERO-3
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 18 Apr 2016 Results of a pooled biomarker analysis form BOLERO-1 and BOLERO-3 trials (n=549) published in the Journal of Clinical Oncology
  • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium (n = 569).
  • 13 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top